IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Net Worth Advisory Group

Net Worth Advisory Group decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,002 shares of the company’s stock after selling 33 shares during the quarter. Net Worth Advisory Group’s holdings in IDEXX Laboratories were worth $414,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. FSA Wealth Management LLC acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth about $25,000. Rialto Wealth Management LLC acquired a new position in IDEXX Laboratories in the fourth quarter valued at approximately $30,000. Retirement Wealth Solutions LLC purchased a new position in IDEXX Laboratories in the fourth quarter valued at approximately $31,000. Ashton Thomas Securities LLC purchased a new position in IDEXX Laboratories in the third quarter valued at approximately $37,000. Finally, Kestra Investment Management LLC acquired a new stake in IDEXX Laboratories during the fourth quarter worth approximately $38,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity

In related news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.18% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on IDXX shares. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Bank of America raised their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Piper Sandler boosted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Barclays raised their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Finally, Morgan Stanley reduced their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Stock Down 2.2 %

IDXX opened at $426.69 on Wednesday. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $552.20. The business has a 50 day moving average price of $438.11 and a two-hundred day moving average price of $448.27. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The company has a market cap of $34.70 billion, a PE ratio of 39.99, a P/E/G ratio of 3.41 and a beta of 1.39.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.